Racura Oncology (RAC) Q4 2026 TU earnings summary

Executive summary

• Advanced RC220 clinical development with first patient treated in Phase 1 HARNESS-1 trial for EGFR-mutated NSCLC.

• Presented new preclinical data at AACR 2026 showing RC220's c-MYC silencing mechanism.

• CPACS Phase 1 trial cleared to escalate to 80mg/m² dose after favorable safety review.

• Raised $34.3 million in cash, funding operations into CY2028.

• Attracted new institutional investor and expanded shareholder base.

Financial highlights

• Cash and equivalents at 30 June 2026: $34.3 million.

• Over 75% of quarterly expenditure ($2.45 million) invested in R&D and drug manufacturing.

• Net cash used in operating activities for the quarter: $(3.05) million.

• Net cash from financing activities for the quarter: $18.0 million.

• Estimated 11.25 quarters of funding available at current burn rate.

Outlook and guidance

• Funding runway extends into CY2028, supporting all committed clinical activities.

• Focus remains on advancing RC220 in AML, EGFR-mutated lung cancer, and anthracycline cardioprotection.